Vanda Pharmaceuticals to Reveal Third Quarter 2025 Results
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has announced that its financial results for the third quarter of 2025 will be disclosed on a Wednesday, marking a significant moment for investors and stakeholders. The anticipated release will occur after market closure on October 29, 2025.
Details of the Conference Call
To facilitate thorough discussion about its performance and future plans, Vanda will host a conference call at 4:30 PM ET on the same day. During this call, management will provide insights into the financial results, highlighting key developments and ongoing corporate activities.
Interested parties can join the conversation by dialing either 1-888-596-4144 for domestic participants or 1-646-968-2525 for those calling internationally. It's essential to use the designated passcode 8728050 to join the call smoothly.
Accessing the Live Broadcast
The conference call will also be available via live broadcast, which will subsequently be archived on Vanda's official website. Investors are encouraged to visit the website ahead of time to ensure they meet the technical requirements for participation.
Replay Availability
A recorded version of the conference call will be accessible shortly after its conclusion on October 29, 2025, beginning at 8:30 PM ET. The replay will remain available until November 5, 2025, at 11:59 PM ET. Domestic callers can access the replay by calling 1-800-770-2030 and international callers should dial 1-609-800-9909, using the same passcode for access.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals is renowned as a pivotal player in the biopharmaceutical sector, specializing in the development and commercialization of advanced therapies designed to meet significant unmet medical needs. Its commitment to innovation remains at the core of its mission to enhance the quality of life for patients worldwide.
For further information, please visit Vanda Pharmaceuticals’ website and connect with the company through their social channels to stay updated on the latest news.
Corporate Contact Information
For any inquiries or more information, Vanda Pharmaceuticals has established clear communication channels. Kevin Moran serves as the Senior Vice President, Chief Financial Officer, and Treasurer at Vanda Pharmaceuticals Inc. He can be reached at 202-734-3400 for corporate inquiries.
The Team Behind Vanda Pharmaceuticals
The Vanda team also includes professionals from Collected Strategies, including Jim Golden, Jack Kelleher, and Dan Moore, who jointly contribute to the company's strategic efforts and communications.
Frequently Asked Questions
When will Vanda Pharmaceuticals announce its Q3 2025 results?
The announcement is scheduled for October 29, 2025, after the market closes.
How can I participate in the conference call?
You can participate by calling 1-888-596-4144 for domestic or 1-646-968-2525 for international access, using passcode 8728050.
Will the conference call be available for replay?
Yes, the replay will be available starting October 29, 2025, at 8:30 PM ET, until November 5, 2025.
What is Vanda Pharmaceuticals' main focus?
Vanda Pharmaceuticals focuses on developing innovative therapies that address significant unmet medical needs and improve patient lives.
Who can I contact for more information?
For inquiries, you may contact Kevin Moran at 202-734-3400.
